Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Fig. 3

Mechanism of IDO1 regulation, function and activity. a Regulation of IDO1 expression in many cells through IFN-γ/JAK/STAT, KAS, NF-κB and PI3K pathways. b IDO1 targeting and mechanism of IDO1 in immune escape of cancer cells. IDO1 promotes the immune escape and progression of cancer mainly through GCN2/eIF2, GLK1/mTOR, AhR to inhibit the function and differentiation of effector T cells, and there are mainly three strategies to target IDO1 in clinical trials for cancer treatment

Back to article page